Promising New Anti-Pruritic Topical Treatment - Full Text View

Sponsored by:	Evangelical Synod Medical Centre
Information provided by:	Evangelical Synod Medical Centre
ClinicalTrials.gov Identifier:	NCT00568204

Purpose

Atomised Methoxymethane-in-Aqua (MEXYN-A) a new topical self-chilled, non-steroidal, non-flammable, pressurised spray which embodies in one simultaneous application, most of the currently recognised and effective chemical, mechanical and thermal anti-pruritic therapies and hydrotherapy.

Condition	Intervention
Pruritus	Device: Mexyn-A

MedlinePlus related topics: Itching

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:	Proof of Concept of MEXYN-A as a New Topical Anti-Pruritic Treatment

Further study details as provided by Evangelical Synod Medical Centre:

Primary Outcome Measures:

Treating Pruritus [ Time Frame: three days ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

measuring itch-free period after applying the new treatment, effect on sleep disturbance [ Time Frame: three days ] [ Designated as safety issue: Yes ]

Enrollment:	239
Study Start Date:	March 2002
Study Completion Date:	September 2005

Arms	Assigned Interventions
1: Experimental Mexyn-A	Device: Mexyn-A Atomised topical self-chilled pressurised spray

Detailed Description:

The primary clinical endpoint was to establish MEXYN-A efficacy and safety in abolishing or reducing pruritus related to cutaneous diseases, insect bites and poison ivy, within few seconds of the application. The secondary endpoint was to measure the itch free period as a result of the new intervention.

Eligibility

Ages Eligible for Study:	5 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Patients suffering from severe itching due to : Atopic Dermatitis, contact dermatitis, psoriasis, urticaria, xerosis, prickly heat, genital pruritus, chicken pox, aquagenic pruritus, lichen planus, poison ivey, insect bites.
Past experience with the use of at least one conventional medication for pruritus or conventional medication for the same disorder patients suffered.

Exclusion Criteria:

Patients who have taken any anti-pruritic drug during the month prior to participation.
Patients who have taken drugs for any reason for 2 days prior to participating in the study.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00568204

Locations

Egypt
Evangelical Synod Medical Centre
Cairo, Egypt, 11111

Sponsors and Collaborators

Evangelical Synod Medical Centre

Investigators

Principal Investigator:	Ihab Akhnoukh	Evangelical Synod Medical Centre
Study Director:	Ashraf Khella	Harpur Memorial Hospital

More Information

Responsible Party:	Evangelical Synod Medical Centre ( Dr Ihab Akhnoukh M.D. )
Study ID Numbers:	EvangelicalSynodMC
Study First Received:	November 30, 2007
Last Updated:	July 12, 2008
ClinicalTrials.gov Identifier:	NCT00568204
Health Authority:	Egypt: Institutional Review Board

Keywords provided by Evangelical Synod Medical Centre:

pruritus, itching, mexyn-a, clearitch, magicool-plus

Study placed in the following topic categories:

Pruritus
Signs and Symptoms
Skin Diseases

Additional relevant MeSH terms:

Skin Manifestations

ClinicalTrials.gov processed this record on January 15, 2009